WO2021107660A1 - 생체 내 지속시간이 연장된 다기능성 다중특이적 멀티머 생체분자 중합체 - Google Patents
생체 내 지속시간이 연장된 다기능성 다중특이적 멀티머 생체분자 중합체 Download PDFInfo
- Publication number
- WO2021107660A1 WO2021107660A1 PCT/KR2020/017029 KR2020017029W WO2021107660A1 WO 2021107660 A1 WO2021107660 A1 WO 2021107660A1 KR 2020017029 W KR2020017029 W KR 2020017029W WO 2021107660 A1 WO2021107660 A1 WO 2021107660A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ubiquitin
- terminus
- protein
- biomolecule
- polymer
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 95
- 238000001727 in vivo Methods 0.000 title claims abstract description 21
- 230000002035 prolonged effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 135
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 120
- 102000044159 Ubiquitin Human genes 0.000 claims abstract description 104
- 108090000848 Ubiquitin Proteins 0.000 claims abstract description 104
- 102000004190 Enzymes Human genes 0.000 claims abstract description 46
- 108090000790 Enzymes Proteins 0.000 claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 230000021615 conjugation Effects 0.000 claims abstract description 20
- 108010068086 Polyubiquitin Proteins 0.000 claims abstract description 19
- 102100037935 Polyubiquitin-C Human genes 0.000 claims abstract description 19
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 14
- -1 antibody Proteins 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 7
- 238000010798 ubiquitination Methods 0.000 claims abstract description 7
- 230000034512 ubiquitination Effects 0.000 claims abstract description 7
- 235000018102 proteins Nutrition 0.000 claims description 108
- 102000005962 receptors Human genes 0.000 claims description 56
- 108020003175 receptors Proteins 0.000 claims description 56
- 229940088598 enzyme Drugs 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 24
- 238000009739 binding Methods 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 9
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 8
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 6
- 102000051325 Glucagon Human genes 0.000 claims description 6
- 108060003199 Glucagon Proteins 0.000 claims description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 6
- 102100040918 Pro-glucagon Human genes 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 6
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 6
- 229960004666 glucagon Drugs 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 claims description 5
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 108010011459 Exenatide Proteins 0.000 claims description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 4
- 108700012941 GNRH1 Proteins 0.000 claims description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 4
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 4
- 102100022831 Somatoliberin Human genes 0.000 claims description 4
- 101710142969 Somatoliberin Proteins 0.000 claims description 4
- 102000011923 Thyrotropin Human genes 0.000 claims description 4
- 108010061174 Thyrotropin Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229940125542 dual agonist Drugs 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 229960001519 exenatide Drugs 0.000 claims description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940040129 luteinizing hormone Drugs 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 229960001319 parathyroid hormone Drugs 0.000 claims description 4
- 239000000199 parathyroid hormone Substances 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 3
- 108010076365 Adiponectin Proteins 0.000 claims description 3
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 3
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 3
- 239000000854 Human Growth Hormone Substances 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 229940118432 Interleukin receptor antagonist Drugs 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 230000008468 bone growth Effects 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims description 3
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 claims description 2
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 claims description 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
- 102000009840 Angiopoietins Human genes 0.000 claims description 2
- 108010009906 Angiopoietins Proteins 0.000 claims description 2
- 102400000068 Angiostatin Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 108010064733 Angiotensins Proteins 0.000 claims description 2
- 102000015427 Angiotensins Human genes 0.000 claims description 2
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 2
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 101800001982 Cholecystokinin Proteins 0.000 claims description 2
- 102100025841 Cholecystokinin Human genes 0.000 claims description 2
- 229940122097 Collagenase inhibitor Drugs 0.000 claims description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 2
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 claims description 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000001617 Interferon Receptors Human genes 0.000 claims description 2
- 108010054267 Interferon Receptors Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 2
- 108010056852 Myostatin Proteins 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 102000017975 Protein C Human genes 0.000 claims description 2
- 108090000103 Relaxin Proteins 0.000 claims description 2
- 102000003743 Relaxin Human genes 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 108010086019 Secretin Proteins 0.000 claims description 2
- 102100037505 Secretin Human genes 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 108010016283 TCF Transcription Factors Proteins 0.000 claims description 2
- 102000000479 TCF Transcription Factors Human genes 0.000 claims description 2
- 102000003790 Thrombin receptors Human genes 0.000 claims description 2
- 102000012607 Thrombomodulin Human genes 0.000 claims description 2
- 108010079274 Thrombomodulin Proteins 0.000 claims description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 2
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229950008486 carperitide Drugs 0.000 claims description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 229940107137 cholecystokinin Drugs 0.000 claims description 2
- 239000002442 collagenase inhibitor Substances 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 102000026898 cytokine binding proteins Human genes 0.000 claims description 2
- 108091008470 cytokine binding proteins Proteins 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 150000002333 glycines Chemical group 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940051026 immunotoxin Drugs 0.000 claims description 2
- 230000002637 immunotoxin Effects 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 231100000608 immunotoxin Toxicity 0.000 claims description 2
- 239000004026 insulin derivative Substances 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Proteins 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 102000005861 leptin receptors Human genes 0.000 claims description 2
- 108010019813 leptin receptors Proteins 0.000 claims description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 229940053128 nerve growth factor Drugs 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 229960002101 secretin Drugs 0.000 claims description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 239000013559 triple agonist Substances 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 230000006510 metastatic growth Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 19
- 239000000758 substrate Substances 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 4
- 102000003960 Ligases Human genes 0.000 abstract description 3
- 108090000364 Ligases Proteins 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 76
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 43
- 230000000694 effects Effects 0.000 description 40
- 239000000203 mixture Substances 0.000 description 35
- 239000000872 buffer Substances 0.000 description 33
- 239000000178 monomer Substances 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 32
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 27
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 27
- 102000016912 Aldehyde Reductase Human genes 0.000 description 26
- 108010053754 Aldehyde reductase Proteins 0.000 description 26
- 102000037865 fusion proteins Human genes 0.000 description 26
- 108020001507 fusion proteins Proteins 0.000 description 26
- 108010058076 D-xylulose reductase Proteins 0.000 description 25
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 238000000746 purification Methods 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 14
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 12
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 12
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 12
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 12
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 12
- 238000011068 loading method Methods 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 239000001488 sodium phosphate Substances 0.000 description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 description 11
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 11
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 8
- 229940027941 immunoglobulin g Drugs 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 7
- 101000684495 Homo sapiens Sentrin-specific protease 1 Proteins 0.000 description 7
- 101710120037 Toxin CcdB Proteins 0.000 description 7
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 102100023653 Sentrin-specific protease 1 Human genes 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010017192 4-hydroxy-4-methyl-2-oxoglutarate aldolase Proteins 0.000 description 5
- 102100029589 Acylpyruvase FAHD1, mitochondrial Human genes 0.000 description 5
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 5
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 5
- 108010069823 Oxaloacetate decarboxylase Proteins 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000012743 protein tagging Effects 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 3
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 3
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 3
- 101710192923 Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 3
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000002669 lysines Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 2
- 101000650779 Boana raniceps Raniseptin-5 Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101100315899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YUH1 gene Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- YNSUUAOAFCVINY-OSUNSFLBSA-N Arg-Thr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YNSUUAOAFCVINY-OSUNSFLBSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 1
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 1
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical class OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100040877 E3 ubiquitin-protein ligase MARCHF5 Human genes 0.000 description 1
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 1
- QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 1
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 1
- 101001039881 Homo sapiens E3 ubiquitin-protein ligase MARCHF5 Proteins 0.000 description 1
- 101001023703 Homo sapiens E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 1
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 1
- OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 1
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- AWOMRHGUWFBDNU-ZPFDUUQYSA-N Met-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N AWOMRHGUWFBDNU-ZPFDUUQYSA-N 0.000 description 1
- JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- 108010024026 Nitrile hydratase Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 101001053878 Phyllomedusa trinitatis Dermaseptin-TR1 Proteins 0.000 description 1
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 101100117359 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSM4 gene Proteins 0.000 description 1
- 101100117358 Schizosaccharomyces pombe (strain 972 / ATCC 24843) doa10 gene Proteins 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 1
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 1
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 1
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010084736 ubiquitin carrier proteins Proteins 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01009—D-Xylulose reductase (1.1.1.9), i.e. xylitol dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01307—D-Xylose reductase (1.1.1.307)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
- C12Y102/03003—Pyruvate oxidase (1.2.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01003—Oxaloacetate decarboxylase (4.1.1.3)
Definitions
- the present invention relates to a method for preparing a biomolecule including a protein into a multimeric polymer. Specifically, the present invention relates to a method for preparing a biomolecule recombinantly expressed from a host cell into a multifunctional multispecific biomolecule polymer having an increased in vivo duration using an ubiquitination system.
- Biomolecules and/or small molecule chemical compounds including proteins, peptides, polypeptides, antibodies, DNA and RNA in multimeric form has various advantages. For example, by linking two or more homologous or heterogeneous proteins using a fusion or cross-linking agent, physicochemical properties such as solubility, gelation, thermal stability and pH stability of the protein are improved. can do.
- laccase and CLEA cross-linked enzyme aggregate formed by being multi-linked through a cross-linking agent showed improved stability and performance during starch oxidation, and another enzyme, nitrile hydratase (nitrile) hydratase) showed an excellent increase in activity in the conversion of acrylonitrile to acrylamide, and did not lose activity during 36 recycling cycles.
- proteins perform complex functions by forming complexes in cells, which is known to be due to the proximity effect of proteins.
- enzymes necessary for decomposing lignocellulose such as cellulase, beta-glucosidase, and hemicellulase, are prepared in the form of a complex mixture using a scaffold.
- One cellulase (Novozymes Cellic® CTec3) is known to exhibit a 3.5-fold or more increased effect on the degradation of lignocellulose.
- such a multimeric protein exhibits a channeling effect. That is, if the enzymes involved in the coupling reaction exist adjacent to each other, the transfer of the intermediate is made efficiently, thereby greatly increasing the efficiency of the entire reaction.
- 10/504,785 relates to the expression of a recombinant gene and purification of the expressed protein, wherein the nucleotides encoding the C-terminal domain of a ubiquitin-like protein (Ubl) are operably linked to the nucleotides encoding the protein of interest. (operatively) preparing the bound fusion protein and expressing it in a host cell is described.
- Korean Patent Application No. 10-2005-0050824 describes the use of ubiquitin as a fusion partner in expressing a recombinant protein.
- 10-2015-0120852 relates to using a ubiquitin column for protein purification, and describes a method for loading a polyubiquitin chain into the column and purifying a protein using in vitro ubiquitination including E2. do.
- US Patent Application No. 12/249,334 is intended to solve the problems of solubility and folding, which are problems in expressing and manufacturing recombinant proteins, and to facilitate expression, isolation, and purification of recombinant proteins and to increase protein activity.
- these methods only describe the use of ubiquitin for protein expression, and do not describe or suggest the production of a multimeric protein, and since the protein to be separated and purified is randomly combined with ubiquitin, separation or analysis efficiency is still has limitations on
- biomolecules such as proteins or peptides, or recombinantly produced proteins or peptides, are unstable molecules that exhibit a short serum half-life.
- these proteins or peptides are very unstable when prepared in aqueous solutions for diagnostic or therapeutic purposes.
- protein or peptide drugs are disadvantageous because of their short serum half-life in vivo and must be administered at a high frequency or at a higher dose.
- frequent administration of the drug causes various side effects and causes discomfort to the patient.
- problems that occur in patients requiring frequent administration of drugs, for example, diabetic patients or patients suffering from multiple sclerosis.
- Various methods for increasing the in vivo stability or half-life of such biomolecules have been studied.
- a component capable of increasing the half-life is covalently attached to a biomolecule such as a protein or peptide.
- a biomolecule such as a protein or peptide.
- attaching polymers such as polyethylene glycol or PEG to polypeptides can increase the serum half-life of these peptides.
- the present inventors have worked diligently to develop a method for preparing a multifunctional multispecific biomolecule polymer having a high degree of integration without inhibiting protein activity, and an increased in vivo duration or half-life.
- the present invention was completed by recombinantly expressing ubiquitin-bound biomolecules from host cells , reacting them with ubiquitination-related enzymes in vitro to form a multifunctional multimeric biomolecule polymer bound to polyubiquitin scaffolds. did.
- Patent Document 1 Korean Patent Application No. 10-2005-0050824
- Patent Document 2 Korean Patent Application No. 10-2015-0120852
- Patent Document 3 US Patent Application No. 12/249,334
- an object of the present invention is to provide multivalent multimeric biomolecules having an increased in vivo duration by binding a target biomolecule to a polyubiquitin scaffold.
- Another object of the present invention is to provide a method for preparing a multifunctional multispecific biomolecule having an increased in vivo duration by binding a target biomolecule to a polyubiquitin scaffold.
- Another object of the present invention is to provide a pharmaceutical composition comprising the multifunctional multispecific biomolecule.
- Another object of the present invention is to provide a method for preparing a pharmaceutical composition comprising the multifunctional multispecific biomolecule.
- the present invention provides a polyubiquitin scaffold formed by covalently bonding two or more ubiquitins, and two or more containing binding moieties specific for different binding sites.
- a multifunctional multispecific biomolecule polymer composed of 10 biomolecules, wherein the biomolecule contains active sites that specifically bind to other biomolecules, small molecule chemical compounds or nanoparticles.
- a multifunctional multispecific multimer living body wherein a carrier extending the in vivo stability and/or duration of the biomolecule is directly bound to the N-terminus or C-terminus of the ubiquitin or bound by a linker.
- Molecular polymers multivalent multispecific multimeric biomolecule complex
- the linker may be a combination of 1 to 30 repetitions of GGGGS or EAAAK, but is not limited thereto.
- the biomolecule bound to the N-terminus of the ubiquitin may be the distal end of the multimeric biomolecule polymer, and the C-terminus or the N-terminus of the ubiquitin, or both. The biomolecule bound to both may be the proximal end of a multimeric biomolecule polymer.
- polymer means a group of monomers in a series of biomolecules linked together.
- the polymer may be linear or branched (branched).
- each polymer chain may be referred to as a "polymer arm.”
- the end of the polymer arm linked to the initiator moiety is the proximal end, and the growing-chain end of the polymer arm is the distal end.
- linker refers to a chemical moiety that connects two groups together.
- the linker may be cleavable or non-cleavable.
- the cleavable linker may be a hydrolysable, enzymatically cleavable, pH sensitive, photolabile, or disulfide linker, among others.
- Other linkers include homobifunctional and heterobifunctional linkers.
- the carrier serves to increase the in vivo duration of the biomolecule, and includes albumin, antibody fragment, Fc domain, transferrin, XTEN (genetic fusion of non-exact repeat peptide sequence), CTP. (carboxy-terminal peptide), PAS (proline-alanine-serine polymer), ELK (elastin-like peptide), HAP (homo-amino acid polymer), GLK (gelatin-like protein), PEG (polyethylene glycol), and It may be at least one selected from the group consisting of fatty acids, but is not limited thereto.
- the polyubiquitin scaffold is a donor ubiquitin in which one or more lysines of ubiquitin are substituted with other amino acids including arginine or alanine and the 6th, 11th, 27th, 29th from the N-terminus
- the lysine at position 33, 48, or 63 may be substituted with other amino acids including arginine or alanine, which may be formed by covalently connecting the receptor ubiquitin.
- the leucine at position 73 from the N-terminus of ubiquitin may be substituted with another amino acid including proline.
- biomolecule refers to molecules having biological activity in a living body.
- the biomolecule is insulin, insulin analog, glucagon, glucagon-like peptides, GLP-1 and glucagon dual agonist, GLP-1 and GIP dual agonist, GLP-1 and glucagon and GIP triple agonist , exendin-4 (exendin-4), exendin-4 analogs, insulin-releasing peptides and analogs thereof, human growth hormone (human growth hormone), growth hormone-releasing hormone (GHRH), growth hormone-releasing peptides , granulocyte colony stimulating factor (G-CSF), anti-obesity peptide, G-protein-coulped receptor, leptin, GIP (Gastric inhibitory polypeptide), interleukins, interleukin receptors, interleukin binding proteins, interferon Leukemia, interferon receptors, cytokine binding proteins, macrophage activator, macrophage peptide, B cell
- binding site refers to a site that is bonded to another material or component
- binding moiety refers to a component including a portion capable of binding to another material or component
- active site refers to a site that induces activity by reacting with a ligand or receptor.
- UCT Ubiquitin C-terminal Tag
- UCT refers to a specific sequence of the C-terminal region of ubiquitin, and UCT is conjugated with a specific lysine of other ubiquitin through covalent bonding.
- the present invention provides (i) recombinant expression of bio-molecules to which a ubiquitin C-terminal tag is fused or linked by a linker from a host cell including a prokaryotic cell or a eukaryotic cell, and (ii) ) adding and reacting E1, E2 and E3 enzymes or E1 and E2 enzymes for ubiquitination to the cell lysates or purified product of the host cell, and a polyubiquitin scaffold, different binding sites two or more biomolecules comprising binding moieties specific for the sites), and a carrier that prolongs the in vivo duration
- the biomolecule is composed of 2 to 10 biomolecules, and has active sites specifically binding to other biomolecules, small molecule chemical compounds or nanoparticles, and the ubiquitin
- a method for preparing a multivalent multispecific multimeric biomolecule complex which is linked to the N-terminus, C-terminus, or both N-terminus and C-terminus by a linker.
- the E2 enzyme binds to the 6th, 11th, 27th, 29th, 33rd, 48th or 63rd lysine from the N-terminus of ubiquitin, or E2-25K ubiquitin conjugation ( ubiquitin conjugating) enzyme or Ucb13-MMS2, which is a ubiquitin-conjugating enzyme complex, but is not limited thereto.
- the ubiquitin C-terminal tag includes two or more ubiquitins repeatedly linked in a head-to-tail or branched type or iso-peptide branch type form.
- the ubiquitin connected in the head-to-tail or branched form may be one in which the glycines at positions 75 and 76 from the N-terminus are substituted with other amino acids including valine.
- the linkage between biomolecular polymers or complexes is made through a polyubiquitin scaffold, and polyubiquitin is a rigid scaffold or linker (rigid scaffold) that maintains spacing and directionality between biomolecules bound thereto. acts as a linker).
- polyubiquitin is a rigid scaffold or linker (rigid scaffold) that maintains spacing and directionality between biomolecules bound thereto. acts as a linker).
- the multifunctional multispecific multimeric biomolecule polymer is provided in combination with a molecule capable of increasing the in vivo duration, thereby increasing the in vivo stability and duration of efficacy of the drug. can be used for manufacturing.
- the biomolecule may be one or more selected from the group consisting of proteins, peptides, polypeptides, antibodies, antibody fragments, DNA and RNA, for example, functionalities modularized in a linear multifunctional multimeric polymer using heterologous proteins can be given
- the multifunctional multispecific multimeric biomolecule polymer is provided in combination with a molecule capable of increasing the in vivo duration, thereby increasing stability and efficacy duration in vivo for the biomolecule. can provide
- FIG. 6 schematically shows the preparation of the linear multifunctional multimeric fusion protein of the present invention and the immobilization and use thereof.
- OAC oxaloacetate decarboxylase
- XDH xylitol dehydrogenase
- TIM triose-phosphate isomerase
- ALD 12 is a result of SDS-PAGE after purification of Aldolase (ALD) prepared according to the present invention by GPC.
- FBP Fructose 1,6-bisphosphatase
- POPG pyruvate oxidase
- 17 is a result of analyzing the activity of oxaloacetate decarboxylase.
- 21 is a result of analyzing the activity of pyruvate oxidase.
- 25 is a result of preparing and confirming hGH in which aspartate is extended at the c-terminus of 76 glycine of the ubiquitin C-terminal tag.
- 26 shows the preparation and confirmation of a polymer starting from E3.
- Figure 27 confirms the manufacturing result of hGH polymer according to the presence or absence of DUB.
- Fig. 28 shows the binding activity of human-derived IgG to beads immobilized with protein A units and beads immobilized with protein A polymers.
- 29 relates to a linear multifunctional multimeric biomolecular polymer structure bound to the N-terminus, C-terminus, or both N-terminus and C-terminus of ubiquitin, respectively, and the preparation results thereof.
- AUC bioabsorption rate
- 31 shows a pcDNA3.1(+) vector to which a gene expressing an Fc based receptor protein is linked.
- Figure 32 shows the results of confirming the expression of the Fc based receptor protein.
- 41 and 42 show the results of confirming the His-SUMO tag removed ubiquitin-IL-1RA.
- Figure 46 shows the conjugation yield analysis results using the ⁇ CE-SDS assay.
- Figure 56 shows the structure of a fusion protein (C-192; comparative group) using a donor protein (D-192), UniStac protein (C-193), and an acceptor protein carrying Human-serum albumin as a carrier.
- 57 shows a graph of blood drug concentration with time after subcutaneous administration of fusion proteins (C-192 and D-192).
- 58 shows a graph of blood drug concentration over time after subcutaneous administration of fusion proteins (C-193 and D-192).
- a ubiquitin C-terminal tag is recombinantly expressed from a host cell including a prokaryotic cell or a eukaryotic cell biomolecules (bio-molecules) bound by a fusion or linker, and (ii) adding and reacting E1, E2 and E3 enzymes or E1 and E2 enzymes for ubiquitination to cell lysates or purified products of the host cell, polyubiquitin scaffold, different binding Two or more biomolecules comprising binding moieties specific for binding sites, and a carrier extending in vivo duration
- a method for preparing a multifunctional multispecific multimeric biomolecule polymer, which is linked at both terminus and C-terminus by a linker is provided.
- an initiator that initiates the formation of a multifunctional multispecific multimeric biomolecule polymer or complex may be a target substrate of E3, E2, E1, free ubiquitin, or E3.
- the E2 enzyme may bind to No. 48 or No. 63 among lysines of ubiquitin, and the E2 enzyme may be an E2-25K ubiquitin conjugating enzyme or a ubiquitin conjugation enzyme complex Ucb13-MMS2.
- each of the biomolecules preferably binds to the N-terminus of the ubiquitin.
- the multimeric biomolecule polymer may be composed of 2 to 30 biomolecules.
- the UniStac reaction of the present invention is schematically shown in FIG. 1 .
- the multifunctional multispecific multimeric biomolecule polymer of the present invention can be prepared in various forms. Specific examples are shown in FIGS. 4, 6 and 7 . That is, the first figure schematically shows the process of preparing the UniStac linear enzyme polymer by reacting the ubiquitin C-terminal-tagged enzyme with the UniStac mixture as shown in FIG. 1 and then filtration. The second figure shows the process of preparing a UniStac enzyme aggregate by reacting the ubiquitin C-terminal-tagged enzyme with a UniStac mixture, followed by precipitation with a crosslinker. 3 schematically shows the process of immobilizing the ubiquitin C-terminal tagged protein on a substrate or bead.
- UCT Ubiquitin C-terminal Tag
- PCR (95°C for 3 minutes, 95°C for 15 seconds - 95°C for 3 minutes, 95°C for 15 seconds - except for the region to be deleted using primers designed to overlap both ends with fusion polymerase (Phusion polymerase, Thermo Fisher Scientific)) 55° C. 1 min - 72° C. 1 min/kb 18 repetitions, 72° C. 5 min, 12° C. 20 min) were performed.
- fusion polymerase Pieris polymerase
- the PCR product was subjected to Dpn1 treatment at 37° C. for 1 hour, and the desired plasmid was obtained after transformation into E. coli DH5 ⁇ (Novagen). All gene constructs were confirmed by commercial DNA sequencing.
- each gene construct was transformed into E. coli BL21 DE3 (Novagen) (XR, TIM, ALD), Rosetta pLysS DE3 (Novagen) (XDH, OAC, POPG), Origami2 DE3 (Novagen) (FBP) strains. was transformed into Cells containing the protein expression plasmid (pET21a, Genscript) were incubated at 37° C. in LB medium (Miller). When the OD 600 value reached about 0.6, protein expression was assayed using 250 ⁇ M isopropyl-beta-D-thiogalactopyranoside (IPTG) and at 16 °C for 20 h. induced.
- IPTG isopropyl-beta-D-thiogalactopyranoside
- the cell pellet was resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl2, 20 mM imidazole) and sonication (50% amplitude) , pluse on 3 sec-off 5 sec, final 15 min). The lysate was then further centrifuged at 14,000 rpm at 4° C. for 30 minutes.
- UniStac reaction a reaction for preparing a fusion protein in the form of a linear multifunctional multimer was named UniStac reaction.
- UniStac reactions total volume 50 ⁇ L were performed in UniStac buffer (25 mM HEPES (Sigma-aldrich), pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), and UniStac mixture for UniStac reactions (0.5 ⁇ M E1, 5 ⁇ M) E2, 1 ⁇ M E3, 4 mM ATP) was added to the UCT protein fusion of the present invention to start the reaction.
- UniStac reaction was carried out by shaking at room temperature for 1 hour.
- the ratio of the protein used in the reaction was carried out at a concentration of 10 ⁇ M to 20 ⁇ M UCT protein fusion (ratio 1:10 to 1:20) per 1 ⁇ M E3 enzyme, which was carried out with at least 10 fusion monomers within 1 hour through the UniStac reaction. is a condition established for the purpose of forming a linear multifunctional multimer.
- E1, E2 and E3 used in the present invention are respectively as follows:
- E2-UniStac was prepared. A recombinant DNA plasmid synthesized by Genscript was used. E2-UniStac reaction was carried out in buffer (50 mM Tris pH8.0, 5 mM MgCl 2 ) conditions, E2-UniStac mixture (1 ⁇ M E1, 10 ⁇ M E2, 4 mM ATP) was dissolved in free ubiquitin solution (20 ⁇ M). was added to initiate the reaction. The E2-UniStac reaction was performed by shaking at room temperature for 1 hour. Fig. 5 shows the results.
- Example 1 Xylose reductase (XR, Xylose reductase) activity and stability analysis
- UniStac reactions were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), and UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP) was added to the XR protein solution. and the reaction was started.
- the UniStac reaction was carried out by shaking at room temperature for 1 hour, and then the catalyst activity was analyzed.
- the catalytic activity of XR was analyzed by measuring the change in absorbance at 340 nm induced by NADH oxidation.
- the reaction for catalytic activity assay was the addition of NADH (2 mM) to a mixture of XR (10 ⁇ M) and xylose (200 mM) in 100 mM NaCl buffer (pH 7.0) containing 1 mM MgCl 2 and 0.02% Tween-20. was started.
- XR is a sample in the form of a monomer that does not include a ubiquitin tag at the c-terminus of XR, and no polymer was formed under the same UniStac mixing conditions.
- Statistical analysis was performed using Prism 6 (GraphPad Software, Inc). The results are shown in FIG. 15 .
- the XR according to the present invention promoted the reduction of D-xylose to xylitol by using NADH as a co-substrate. Absorbance indicates the amount of NADH in solution.
- the UniStac polymer of XR (lower curve) showed faster NADH consumption compared to the monomeric form (upper curve). Both reactions contained the same amount of monomer. Thus, the increased rate of reaction is solely dependent on the covalent bonds between the monomers. As a result, it was confirmed that the activity of the XR UniStac polymer was increased 10-fold compared to the ubiquitin-tagged XR monomer.
- OAC involved in gluconeogenesis is used together with AST-ALT to investigate liver damage.
- UniStac reactions were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), and UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP) was added to the OAC protein solution. and the reaction was started. UniStac reaction was carried out by shaking at room temperature for 1 hour, and then the catalyst activity was analyzed.
- the OAC activity assay was based on a decrease in absorbance (340 nm) as NADH consumption progressed under the following conditions: 45 mM TEA buffer pH8.0, 0.45 mM MnCl 2 , 2 mM NADH, 11 U of LDH, 5 ⁇ M OAC, 2.5 mM.
- OAC is a sample in the form of a monomer that does not include a ubiquitin-tag at the OACc-terminus, and does not form a polymer under the same UniStac mixing conditions.
- Statistical analysis was performed using Prism 6 (GraphPad Software, Inc). The results are shown in FIG. 17 .
- XDH is an enzyme belonging to the D-Xylose catabolism pathway, and is known to convert xylitol, a product of XR, into xylulose using NAD + .
- UniStac reactions were first performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ) and UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP) was added to the XDH protein solution to start the reaction. UniStac reaction was carried out by shaking at room temperature for 1 hour, and then the catalyst activity was analyzed.
- XDH activity was determined by monitoring NAD + reduction at 340 nm. The reaction was initiated by adding NADH (2 mM) to a mixture of XDH (20 ⁇ M) and xylose (200 mM) in 100 mM NaCl buffer (pH 7.0) containing 1 mM MgCl 2 and 0.02% Tween-20.
- XDH is a sample in the form of a monomer that does not contain a ubiquitin-tag at the C-terminus of XDH, and does not form a polymer under the same UniStac mixing conditions.
- Statistical analysis was performed using Prism 6 (GraphPad Software, Inc). The results are shown in FIG. 19 .
- the XDH UniStac polymer (upper curve) at pH 5.5 showed a higher NADH+ consumption rate compared to its monomeric form (lower curve). Both reactions contained the same amount of monomer. Thus, the difference in activity depends solely on the covalent bond between the monomers. As a result, it was confirmed that the activity of the XDH UniStac polymer was increased 10-fold compared with the ubiquitin-tagged XDH monomer (XDH).
- POPG is known to be used to investigate liver damage by detecting enzymes such as AST-ALT, an enzyme involved in gluconeogenesis.
- UniStac reactions were first performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), followed by UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP). ) was added to the POPG protein solution to start the reaction. UniStac reaction was carried out by shaking at room temperature for 1 hour, and then the catalyst activity was analyzed.
- UniStac buffer 25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2
- UniStac mixture 0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP.
- H 2 O 2 produced by the POPG oxidation of pyruvate by ABTS was measured.
- the reaction was pyruvate (100 mM), pyrophosphate (6 mM), ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) in sodium phosphate buffer. ) (10 mM) and horseradish peroxidase (HRP) (0.2 U/mL) mixture was initiated by addition of POPG (5 ⁇ M).
- POPG monomer is a sample of monomer behavior that does not have a ubiquitin tag at the c-terminus of POPG, and does not form a polymer under the same UbiStac mixing conditions.
- Statistical analysis was performed using Prism 6 (GraphPad Software, Inc).
- POPG upper curve
- POPG monomeric form
- Both reactions contained the same amount of monomer.
- the difference in activity depends solely on the covalent bond between the monomers.
- Triosephosphate isomerase TIM
- fructose bisphosphate aldolase ALD
- fructose bisphosphatase FBP
- DHAP dihydroxyacetone phosphate
- UniStac enzyme synergy analysis was performed by measuring Fructose-6-Phosphate (F6P), TIM product, ALD and FBP enzyme complex.
- F6P is isomerized to glucose-6-phosphate (G6P) by phosphoglucose isomerase (PGI), and an equal amount of NAD + this glucose-6-phosphate di modified by Glucose-6-phosphate dehydrogenase (G6PDH).
- Enzyme activity was measured in HEPES buffer conditions (200 mM HEPES pH7.5, 10 mM MgCl 2 , 0.5 mM MnCl 2 , 1 mM CaCl 2 ) in 4 ⁇ M TIM, ALD and FBP enzyme complex mixture with 2.5 mM enzyme complex (Dihydroxyacetone phosphate, DHAP), 20 U/mL assay enzymes (PGI and G6PDH), and 2.5 mM NAD + enzyme complex were added to determine the amount of newly produced NADH by measuring at 340 nm.
- the enzyme complex mixture is a sample in the form of a monomer that does not have a ubiquitin tag at the enzyme C-terminus and does not form a polymer under the same UniStac mixture conditions.
- Statistical analysis was performed using Prism 6 (GraphPad Software, Inc). At the indicated time point, the reaction was terminated and the amount of F6P was measured using phosphoglucose isomerase (PGI) using NAD+ to convert F6P to glucose-6- phosphate (G6P). Absorbance indicates the amount of F6P.
- PGI phosphoglucose isomerase
- FIG. 23 The experimental results are shown in FIG. 23 .
- the UniStac polymer (upper curve) of three different enzymes exhibited 5-fold higher activity than the monomer enzyme mixture (lower curve), confirming the synergistic effect of UniStac enzymes.
- 22 shows the resultant structure (UniStac Polymer) in which three enzymes, TIM, ALD and FBP are combined.
- a biomolecule tagged with ubiquitin C-terminus was synthesized.
- a polymer containing hydroxylamine polyethylene glycol
- the oxime linkage can be used as a tool capable of polymeric drug delivery systems.
- UniStac reactions (50 ⁇ l total volume) were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ) and UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2, 1 ⁇ M E3, 4 mM ATP) was added to the protein A (Protein A) or protein G (Protein G) solution to start the reaction.
- Recombinant DNA plasmids containing sequences corresponding to protein A (GenBank ID-AAB05743.1) and protein G (CAA27638.1) synthesized by Genscript were used. UniStac reaction was performed by shaking at room temperature for 1 hour, and then SDS-PAGE was performed.
- Example 8 hGH with aspartic acid extended at the c-terminus of 76 glycine of the ubiquitin C-terminal tag
- each gene construct was transformed into an E. coli BL21 DE3 (Novagen) strain.
- hGH SEQ ID NO: 18
- Cells containing the protein expression plasmid (pET21a, Genscript) were incubated at 37° C. in LB medium (Miller). When the OD 600 value reached about 0.6, protein expression was assayed using 250 ⁇ M isopropyl-beta-D-thiogalactopyranoside (IPTG) and at 16 °C for 20 h. induced.
- the cell pellet was resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl 2 , 20 mM imidazole) and sonication (50% amplitude) , pluse on 3 sec-off 5 sec, final 15 min). The lysate was then further centrifuged at 14,000 rpm at 4° C. for 30 minutes.
- UniStac reactions (50 ⁇ L total volume) were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2 (Ubch5a or Ubch7), 1 ⁇ M E3) , 4 mM ATP) was added to the protein solution to initiate the reaction.
- the UniStac reaction was shaken at room temperature for 1 hour, and then SDS-PAGE was performed.
- Example 10 Polymer preparation of hGH with and without DUB
- UniStac reaction to confirm the polymer formation of the biomolecule hGH was performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ), UniStac mixture (1 ⁇ M E1, 5 ⁇ M E2 (ubch5a), The reaction was started by adding 1 ⁇ M E3, 4 mM ATP) to the 20 ⁇ M hGH protein solution.
- E2-UniStac reaction without E3 was performed in E2-UniStac buffer (50 mM Tris pH 8.0, 5 mM MgCl 2 ), E2-UniStac mixture (1 ⁇ M E1, 10 ⁇ M E2 (Ucb13-MMS2 complex), 4 mM ATP) was added to the 20 ⁇ M hGH protein solution to initiate the reaction.
- reaction was carried out simultaneously under the condition without DUB (YUH1) and the condition containing 2 ⁇ M of DUB (YUH1). All reactions were performed by shaking at room temperature for 1 to 4 hours, and then confirmed by SDS-PAGE.
- UniStac reactions to make Protein A polymer were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ). The reaction was started by adding the UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2 (Ubch5a or Ubch7), 1 ⁇ M E3, 4 mM ATP) to the Protein A protein solution. The UniStac reaction was shaken at room temperature for 1 hour, then mixed with 50% latex beads in a 1:1 ratio and then shaken at room temperature for 4 hours to immobilize the Protein A polymer to the beads.
- UniStac buffer 25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 .
- the reaction was started by adding the UniStac mixture (0.5 ⁇ M E1, 5 ⁇ M E2 (Ubch5a or Ubch7), 1 ⁇ M E3, 4 mM ATP) to
- the binding activity of human-derived IgG to the beads immobilized with the protein A polymer was increased by 15% or more, compared to the beads immobilized with the Protein A unit by proceeding in the same manner without adding the UniStac mixture. confirmed that it has been
- Example 12 Preparation of a linear polyvalent biomolecule polymer bound to the N-terminus, C-terminus, or both N-terminus and C-terminus of ubiquitin, respectively
- donor ubiquitin SEQ ID NO: 18
- acceptor ubiquitin SEQ ID NO: 19
- donor ubiquitin SEQ ID NO: 18
- acceptor ubiquitin SEQ ID NO: 20
- the receptor ubiquitin is a form in which the 73rd leucine is substituted with proline, and the remaining lysines except for the 48th of the receptor ubiquitin in FIG. 29 (c) or the 63rd lysine in FIGS. 29 (a) and (b) are substituted with arginine. It is in the form of an extension of aspartate or a biomolecule (hGH) at the C-terminus.
- hGH biomolecule
- UniStac reactions (FIGS. 29(a) and (b)) were performed in UniStac buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl 2 ) and UniStac mixture (1 ⁇ M E1, 5 ⁇ M E2 (Ubc13-MMS2) complex), 4 mM ATP) was added to a mixed solution of 10 ⁇ M acceptor ubiquitin protein and donor ubiquitin protein (total ubiquitin concentration of 20 ⁇ M) to start the reaction.
- UniStac reaction shows that under the same conditions as the reaction, E2 was replaced with E2-25K instead of the Ubc13-MMS2 complex, and the receptor ubiquitin was replaced with a protein having only the 48th Lys instead of the 63rd to initiate the reaction.
- the UniStac reaction was performed by shaking at 27° C. for 4 hours, and then confirmed by SDS-PAGE.
- the His-sumo-Ub-hGH type protein was used as a Ub-hGH type receptor ubiquitin obtained by cleaving His-sumo using the SENP1 enzyme, and the remaining SENP1 was included in the UniStac reaction. His-sumo of the donors hGH, Ubc13, and MMS2 was also cut out and it was confirmed that there was a band shift of dimer and E2 (Ubc13, MMS2) after reaction.
- diubiquitin-albumin OGB1
- albumin OGB3
- Diubiquitin-albumin was administered at 0.833 mg/kg and albumin at 1 mg/kg, and there were 12 males per group.
- Blood collection for blood drug concentration analysis was carried out before administration (Blank) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours (12 points in total) after administration, 3 animals per group. .
- the control group consisted of 5 males, and blood was collected 1 and 24 hours after administration. The collected blood was separated from serum and stored cryogenically frozen at -70 ⁇ 10°C. Analysis of drug concentrations from samples collected by time was measured with the Human serum albumin ELISA kit.
- a dilution sera obtained by mixing a dilution buffer (1x PBS, 1% BSA) with a 1:1 rat serum was used. Diubiquitin-albumin was diluted in serum for dilution from 800 ng/mL to 15.625 ng/mL and dispensed into each well. Each sample was diluted to a final 1:1 dilution serum using rat rat serum and a dilution buffer, and dispensed into each well.
- An antibody mixture solution was prepared by diluting the Capture and Detector antibodies of the Human serum albumin kit in the antibody-diluted CP solution. 100 ⁇ l of the antibody mixture solution was dispensed into each well and incubated at room temperature for 1 hour at 400 rpm. When the incubation was completed, the washing solution was dispensed into each well of 300 ⁇ L and the process of shaking off was repeated 3 times. Dispense 100 ⁇ L of TMB substrate solution into each well, incubate at room temperature for 10 minutes and 400 rpm, and dispense 100 ⁇ L of Stop solution into each well, put into the instrument, and measure absorbance (OD450).
- Albumin was diluted from 100 ng/mL to 2.5 ng/mL and dispensed into each well, and the rest of the sample dilution and experimental procedure were performed in the same manner to measure absorbance.
- a calibration curve was calculated with 4 parameters based on the absorbance values measured for each concentration, and the drug concentration in the serum was finally calculated based on the absorbance values measured from the sample compared to the calibration curve.
- Pharmacokinetic parameters were calculated using Phoenix WinNonlin (Ver. 8.1, Pharsight-A Certara company, U.S.A.) for the results of measuring the concentration of the test substance in serum to evaluate the pharmacokinetics.
- diubiquitin-albumin (OGB1) exhibited a higher plasma concentration.
- the group administered with diubiquitin-albumin (OGB1) increased AUC by 1.8 times and Cmax by more than twice as compared to the group administered with albumin (OGB3). Therefore, it can be seen that the diubiquitin-albumin polymer of the present invention has a better pharmacokinetic effect at a lower concentration.
- the biomolecule polymer of the present invention is provided in combination with a molecule capable of increasing duration in vivo, so that it can be used in the manufacture of pharmaceutical compositions requiring increased duration of efficacy in vivo.
- Example 14 Preparation of recombinant expression plasmid DNA capable of expressing Fc-based receptor protein (receptor protein)
- a fusion protein in which a carrier was directly bound to the C-terminus of the receptor ubiquitin was prepared by the following method.
- An antibody fragment (IgG Fc domain) was used as a carrier protein of the fusion protein, and the fusion protein is referred to as "Fc-based receptor protein".
- pcDNA3.1(+) vector is an expression vector for animal cells having a CMV promoter and an ampicillin resistance gene.
- Figure 31 shows a pcDNA3.1 (+) vector to which a gene expressing an Fc-based receptor protein is linked.
- the nucleotide sequence and amino acid sequence expressing the Fc-based receptor protein are shown in Tables 3 and 4 below.
- IgG ⁇ (SP)-Fc-based receptor protein sequence Signal peptide (IgG ⁇ ) (SEQ ID NO: 22) ATGGAAACTG ATACTCTGCT GCTGTGGGTG CTGCTGCTGT GGGTGCCCGG CTCAACTGGT Ub (A) receptor ubiquitin (SEQ ID NO: 23) ATGCAGATCT TCGTGAGGAC CCTGACAGAT CGGACCATCA CACTGGAGGT GGAGCCAAGC GACACCATCG AGAACGTGAG GGCCAGAATC CAGGACCGGG AGGGCATCCC CCCTGATCAG CAGAGACTGA TCTTCGCTGG CCGCCAGCTG GAGGACGGGT AGCTGCT GAGGACGGTG GGTACACTGAGACC CGGAT Hinge (IgG1) (SEQ ID NO: 24) GAGCCAAAAT CTTGTGACAA AACTCATACA TGTCCC Fc (IgG1) (SEQ ID NO: 25) CCATGTCCCG CACCTGAACT GCTGGGCG
- IgG ⁇ (SP)-Fc-based receptor protein amino acid sequence Signal peptide (IgG ⁇ ) (SEQ ID NO: 26) Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly Ub(A) receptor ubiquitin (SEQ ID NO: 27) Met Gln Ile Phe Val Arg Thr Leu Thr Asp Arg Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Arg Ala Arg Ile Gln Asp Arg Glu Gly Ile Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Arg Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn IleGlnLysGluSerThrLeuHisLeuValLeuArgProArgValValAsp Hinge (IgG1) (SEQ ID NO: 28) Glu Pro Lys Ser Cy
- the above Fc-based receptor protein recombinant expression vector was obtained.
- Fc-based receptor protein plasmid DNA was put into DH5 ⁇ competent cells and transformed by heat shock treatment at 42 °C for 1 minute, and LB containing 100 ⁇ g/mL Ampicillin It was plated on solid medium.
- the plated LB solid medium plate was incubated at 37 °C for at least 16 hours to secure colonies. After taking a single colony and inoculating it in 5 mL of LB medium, it was incubated at 37 °C and 220 rpm for 16 hours. A part of the culture medium was inoculated into LB medium containing ampicillin, and then incubated at 37 °C and 220 rpm for 16 hours. The culture medium was centrifuged at 3,500 rpm for 30 minutes to obtain an E.
- a plasmid DNA pellet was obtained from the DNA turbid solution obtained using a purification column of a DNA extraction kit (QIAGEN) and dried naturally. Cell culture water (Sigma Aldrich) was added to the dried DNA pellet and dissolved, followed by filtration with a 0.22 ⁇ m filter. The final extracted plasmid DNA was used for protein expression after measuring the DNA concentration and purity using a nano-drop instrument (IMPLEN).
- IMPLEN nano-drop instrument
- Expi293F human cells are derived from the Human Embryonic Kidney 293 cell line, and have high transfection and high protein expression efficiency.
- Expi293F Inoculate Expi293F (Gibco) cells at 3 x 10 6 viable cells/mL 24 hours prior to the transfection process, mounted on an orbital shaker in an 8% CO 2 incubator, 37 °C, 80 % humidity or higher, 95 Incubated for 24 hours under rpm (50-mm shaking diameter) conditions.
- Transfection was carried out by slowly dispensing into a 1L flask inoculated to 3 x 10 6 viable cells/mL. 8 % CO 2 It was mounted on an orbital shaker in an incubator and incubated for 18 hours at 37 °C, 80 % humidity or higher, 95 rpm (50-mm shaking diameter) conditions. After 18 hours, 1.2 mL of Enhancer 1 (Gibco) and 12 mL of Enhancer 2 (Gibco) were added, respectively, and placed on an orbital shaker in an 8 % CO 2 incubator at 37 °C, 80 % humidity or higher, 95 rpm. (50-mm shaking diameter) conditions were cultured for 7 days.
- Enhancer 1 Enhancer 1
- Enhancer 2 Enhancer 2
- the culture medium obtained above was centrifuged at 3,500 rpm for 30 minutes or more to obtain only the Fc-based receptor protein expression culture medium except for the cell pellet.
- the obtained culture solution was filtered through a filter to remove impurities.
- 80 ⁇ L was taken, 20 ⁇ L of 5X non-reducing sample loading dye was added, mixed, and left at 95 degrees for 10 minutes.
- the membrane was subjected to blocking in 1X PBST (Phosphate Buffer Saline with Tween 20) containing 5% skim milk to remove non-specific reactions while gently shaking for 1 hour.
- PBST Phosphate Buffer Saline with Tween 20
- the binding goat anti-rabbit IgG (H+L) and HRP were used to confirm the specific expression of the Fc-based receptor protein, and the results are shown in Fig. Negative Control does not include plasmid DNA. sample that is not
- the Fc-based receptor protein culture expressed above was loaded onto a MabSelect Prism A (Cytiva) column equilibrated with Equilibrium buffer (20 mM Sodium phosphate, 150 mM NaCl, pH 7.4). Remove impurities that are not bound to the column using Equlibration buffer, and use Elution buffer 1 (50 mM Sodium acetate at pH 4.5) and Elution buffer 2 (50 mM Sodium acetate at pH 4.0) to step elution the receptor. The protein was recovered. 1 M Tris is added to the recovered receptor protein to bring the recovered protein to a pH of 7.5.
- the receptor protein recovered after pH titration was subjected to dialysis with 25 mM Tris and pH 7.5 buffer, followed by ultrafiltration.
- the results of receptor protein purification through SDS-PAGE using 10% in-house gel were confirmed, and the results are shown in FIGS. 34 and 35 .
- Example 16 Expression and purification of ubiquitin-IL-1RA protein (donor protein)
- a ubiquitin-biomolecule protein in which a biomolecule is directly bound to the C-terminus of the donor ubiquitin was prepared as follows.
- the ubiquitin-biomolecular protein-encoding gene sequence into the His-SUMO tag pET21a vector 0.5 ⁇ L of the plasmid into which the gene was inserted was injected into a competent cell, E. coli BL21(DE3) 50 placed in an E-tube containing ⁇ L. Thereafter, the mixture was mixed by tapping and left in ice for 20 minutes. To give a thermal shock, the E-tube was placed in a water bath at 42° C. for 50 seconds, and then left in ice for 5 minutes. Thereafter, 300 ⁇ L of fresh LB medium was added to the E-tube and incubated for 1 hour in a 37 shaking incubator to complete transformation.
- the transformed cells were spread on an LB plate containing 1/1000 of ampicillin at a concentration of 100 mg/ml in BSC and cultured overnight at 37° C. in a stationary incubator. After that, the resulting single colony was inoculated in TB medium in 100 mL containing 1/1000 of ampicillin at a concentration of 100 mg/ml and seed cultured at 37° C., 220 rpm for 6 hours.
- ubiquitin-IL-1RA protein (Donor, D-192) containing IL-1RA as a biomolecule
- 3 L In-house containing 100 mg/ml of ampicillin at a concentration of 100 mg/ml In-house It was inoculated in TB medium at a ratio of 1:100 and main culture was performed.
- Biocanvas fermentor (Centrion) was used at 37 °C, dissolved oxygen (Dissolved Oxygen) 40% for 4 hours, and induction was performed with 1 M IPTG stock at a final concentration of 200 ⁇ M.
- the RPM of the impeller was automatically adjusted to 300 ⁇ 700rpm during the incubation time to adjust the dissolved oxygen amount of the culture medium to 40%. After induction, incubation was continued for 14 hours and the culture was terminated. After culturing, the culture solution was centrifuged at 7000 g for 30 minutes to secure E. coli wet cells.
- the ubiquitin-IL-1RA protein was purified by the following procedure (FIG. 37).
- Lysate was loaded on Ni-sepharose resin (Cytiva). After loading the sample, the non-specific protein was sufficiently washed and removed using a wash buffer (20 mM sodium phosphate, pH 7.0, 0.02 M imidazole). Thereafter, the Hig-SUMO tag-attached ubiquitin-IL-1RA protein was recovered using an elution buffer (20 mM sodium phosphate, pH 7.0, 0.2 M imidazole). The recovered His-SUMO-tagged ubiquitin-IL-1RA protein was subjected to dialysis with 20 mM sodium phosphate, pH 7.0 buffer to remove imidazole. Purification of the donor protein through the Ni column was confirmed by SDS-PAGE, and the results are shown in FIGS. 38 and 39 .
- His-SUMO-tagged ubiquitin-IL-1RA protein and SENP1 were subjected to SENP1 enzyme digestion at a ratio of 100 mg of ubiquitin-IL-1RA protein: 1 mg of SENP1.
- the concentration of the recovered protein by Ni-purification was quantified, and the corresponding recombinant SNEP1 was mixed based on the amount of ubiquitin-IL-1RA protein to which His-SUMO tag was attached.
- the reaction mixture was left at room temperature (15-25° C.) for 1 hour.
- the result of confirming the enzymatic degradation of SENP1 by SDS-PAGE is shown in FIG. 40 .
- the reaction mixture was loaded on Ni-sepharose resin (Cytiva) equilibrated with Equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.02 M imidazole).
- Equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.02 M imidazole).
- Sample loading was performed, and the His-SUMO tag truncated ubiquitin-IL-1RA protein was allowed to flow through.
- the remaining ubiquitin-IL-1RA protein was recovered using an equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.02 M imidazole), and the recovered ubiquitin-IL-1RA protein was mixed with 20 mM sodium phosphate, pH Dialysis was performed with 7.0 buffer to remove imidazole.
- FIGS. 41 and 42 The results of confirming the process in which His-SUMO is removed by SDS-PAGE are shown in FIGS. 41 and 42 .
- the ubiquitin-IL-1RA protein recovered in the previous step was loaded onto an anion exchange column equilibrated with Equilibrium buffer (20 mM sodium phosphate, pH 7.0 buffer). The ubiquitin-IL-1RA protein was allowed to flow through. The recovered ubiquitin-IL-1RA protein was subjected to ultrafiltration to a final 10 mg/mL. The results of the anion exchange resin process for polishing are shown in FIGS. 43 and 44 .
- Conjugation was performed using the acceptor protein produced in Example 18 and the donor protein produced in Example 19.
- the molar ratio of acceptor and donor protein was 1:3.
- the receptor protein can be set to 10 ⁇ M to 50 ⁇ M.
- E1, E2, E3, and ATP were added to the UniStac mixture to start the reaction. The reaction was carried out at 25° C. for 16 hours in a stationary state.
- the result of the conjugation reaction (C-193) was qualitatively analyzed by loading 1.12 ⁇ g of the receptor on 4 to 12% gradient SDS-PAGE, and the results are shown in FIG. 45 .
- reaction step Sample Correlative Area Conjugation yield (%) before reaction receptor protein 6092.70 97.21 Conjugate (C-193) 0.00 after reaction receptor protein 169.70 Conjugate (C-193) 11150.76
- the conjugate was loaded onto an anion exchange chromatography column equilibrated with Equilibrium buffer (25 mM sodium phosphate, pH 7.0 buffer). Elution buffer (25 mM sodium phosphate, pH 7.0, 250 mM NaCl) was used to recover the conjugation, and the results are shown in FIGS. 50 and 51 .
- the conjugate (C-193) was formulated with a formulation buffer (4.6 mM Histidine, 5.7 mM Tris, pH 7.5, 10 mM Arginine, 0.1 g/mL trehalose) through dialysis.
- the final UniStac product was prepared by dilution to 1.1 mg/mL and 0.5 mg/mL.
- the produced samples were stored in a -70 °C deep freezer.
- native-PAGE analysis was performed using 4-15 % T/G-PAG-BC non-SDS and Tris-Glycine Native Running Buffer. Samples were loaded in each of 4.5 ⁇ g on the prepared PAGE, and the results are shown in FIG. 53 .
- the degree of fragment inclusion in the C-193 DS sample was analyzed using ⁇ CE-SDS (Perkin Elmer Labchip GX II Touch.) analysis. After sample pretreatment was performed using the HT Protein Express Reagent Kit (Perkin Elmer), analysis was performed using the Protein Express Assay Labchip (Perkin Elmer), and the results are shown in Table 7 and FIG. 54 below.
- the monomer purity was calculated using Equation 2 and shown in Table 7, confirming the high monomer purity of 98% or more.
- the degree of inclusion of high molecular weight contained in the C-193 DS sample was analyzed using SEC-HPLC column and Alliance e2695 XC HPLC instrument. About 30 ⁇ g of the C-193 DS sample was injected into each prepared column for analysis, and the results are shown in Table 8 and FIG. 55 below.
- Example 19 Comparison of pharmacokinetics of fusion proteins (C-192, C-193 and D-192)
- a fusion protein (C-192) was prepared using the donor protein (D-192), UniStac protein (C-193), and an acceptor protein using Human-serum albumin as a carrier.
- the structures of the three samples are shown in FIG. 56 below.
- the Human IL-1RA ELISA kit (Abcam, UK) having specific reactivity to IL-1RA was used.
- 50 ⁇ L of the standard material and serum for each time period was dispensed in 96 well pate, and then 50 ⁇ L of the antibody cocktail provided by the Human IL-1RA ELISA kit was dispensed into each well in a 25°C mixing device (Thermo Micromixer).
- the reaction was carried out at 400 rpm for 1 hour.
- the solution in the plate well was discarded and shaken so as not to leave any residue.
- dispensing 300 ⁇ L of washing solution into each well discarding and shaking was repeated 3 times.
- 100 ⁇ L of the coloring agent into each well the mixture was reacted at 400 rpm at 25° C. for 10 minutes.
- the fusion protein in which albumin and Fc carrier are fused has excellent pharmacokinetic properties by increasing half-life, AUC, Tmax, and Cmax, and can be utilized as an excellent drug that can be applied to a desired site with a small dose.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
UCT 단백질 융합체 | 분자량 (kDa) | 서열번호 |
Xylose Reductase (XR) | 57.382 | 서열번호: 2 |
Xylitol dehydrogenase (XDH) | 59.1 | 서열번호: 3 |
Oxaloacetate decarboxylase (OAC) | 44.6 | 서열번호: 4 |
Triose-phosphate isomerase (TIM) | 47.6 | 서열번호: 5 |
Aldolase (ALD) | 55.563 | 서열번호: 6 |
Fructose 1,6-bisphosphatase (FBP) | 49.3 | 서열번호: 7 |
Pyruvate oxidase (POPG) | 86.032 | 서열번호: 8 |
구분 | 명칭 | 서열번호 |
E1 | Yeast UBE1 | 서열번호: 9 |
E2 | Ubch5a [ Homo sapiens] (UniProtKB - P51668) | 서열번호: 10 |
Ubch7 [ Homo sapiens] (UniProtKB - P68036) | 서열번호: 11 | |
E2-25K [ Homo sapiens] (UniProtKB - P61086) | 서열번호: 12 | |
Ubc13 [ Saccharomyces cerevisiae] (UniProtKB - P52490) | 서열번호: 13 | |
MMS2 (UEV - Ubiquitin-conjugating enzyme variant) | 서열번호: 14 | |
E3 | RSP5 (UniProt ID. P39940) | 서열번호: 15 |
DOA10 (UniProt ID. P40318) | 서열번호: 16 | |
MARCH5 (UniProt ID. Q9NX47) | 서열번호: 17 |
IgGκ(SP)-Fc-based 수용체 단백질 염기 서열 | |
Signal peptide (IgGκ)
(서열번호 22) |
ATGGAAACTG ATACTCTGCT GCTGTGGGTG CTGCTGCTGT GGGTGCCCGG CTCAACTGGT |
Ub (A)수용체 유비퀴틴
(서열번호 23) |
ATGCAGATCT TCGTGAGGAC CCTGACAGAT CGGACCATCA CACTGGAGGT GGAGCCAAGC GACACCATCG AGAACGTGAG GGCCAGAATC CAGGACCGGG AGGGCATCCC CCCTGATCAG CAGAGACTGA TCTTCGCTGG CCGCCAGCTG GAGGACGGAA GGACCCTGAG CGATTACAAT ATCCAGAAAG AGTCTACACT GCACCTGGTG CTGAGACCGC GCGTCGTGGA T |
Hinge (IgG1)(서열번호 24) | GAGCCAAAAT CTTGTGACAA AACTCATACA TGTCCC |
Fc (IgG1)(서열번호 25) | CCATGTCCCG CACCTGAACT GCTGGGCGGA CCTAGCGTGT TTCTGTTCCC ACCTAAGCCA AAGGACACCC TGATGATCTC CAGGACCCCC GAGGTGACAT GCGTGGTGGT GGACGTGAGC CACGAGGACC CCGAGGTGAA GTTCAACTGG TACGTGGATG GCGTGGAGGT GCATAATGCC AAGACAAAGC CAAGGGAGGA GCAGTACAAC AGCACCTATC GGGTGGTGTC TGTGCTGACA GTGCTGCACC AGGACTGGCT GAACGGCAAG GAGTATAAGT GCAAGGTGTC TAATAAGGCC CTGCCCGCTC CTATCGAGAA GACCATCTCC AAGGCCAAGG GCCAGCCAAG AGAGCCCCAG GTGTACACAC TGCCCCCTAG CCGCGACGAG CTGACCAAGA ACCAGGTGTC TCTGACATGT CTGGTGAAGG GCTTCTATCC TTCTGATATC GCTGTGGAGT GGGAGTCCAA TGGCCAGCCA GAGAACAATT ACAAGACCAC ACCACCCGTG CTGGACTCTG ATGGCTCCTT CTTTCTGTAT TCCAAGCTGA CCGTGGATAA GAGCAGATGG CAGCAGGGCA ACGTGTTCTC CTGTAGCGTG ATGCATGAAG CACTGCATAA TCACTATACC CAGAAGTCAC TGTCACTGAG TCCCGGTAAA |
IgGκ(SP)-Fc-based 수용체 단백질 아미노산 서열 | |
Signal peptide (IgGκ)
(서열번호 26) |
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly |
Ub(A)수용체 유비퀴틴
(서열번호 27) |
Met Gln Ile Phe Val Arg Thr Leu Thr Asp Arg Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Arg Ala Arg Ile Gln Asp Arg Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Arg Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
IleGlnLysGluSerThrLeuHisLeuValLeuArgProArgValValAsp |
Hinge (IgG1)(서열번호 28) | Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro |
Fc (IgG1)(서열번호 29) | Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys |
pH
Meter |
Acetate
(mg/L) |
Glucose
(mg/L) |
Glycerol
(mg/L) |
Mg
2+
(mg/L) |
P
(mg/L) |
Optical density |
7.37 | 193.9 | 0.0 | 1190.7 | 56.2 | 6826.9 | 36.7 |
반응 단계 | 샘플 | Correlative Area | Conjugation yield (%) |
반응 전 | 수용체 단백질 | 6092.70 | 97.21 |
결합체(C-193) | 0.00 | ||
반응 후 | 수용체 단백질 | 169.70 | |
결합체(C-193) | 11150.76 |
UniStac 샘플 농도 | Migration time (sec) | Corr. Area | 순도 (%) |
1.1 mg/mL | 23.62 | 3527.21 | 98.12 |
0.5 mg/mL | 24.56 | 3616.85 | 98.69 |
샘플 농도 | Retention Time (min) | Area | 순도 % |
1.1 mg/mL | 15.051 | 2234084 | 100.00 |
0.5 mg/mL | 15.081 | 2264850 | 100.00 |
PK 파라미터 | C-192 | C-193 | D-192 |
10 mg/kg | 1 mg/kg | 1 mg/kg | |
T max (hr) | 6 | 10 | 1 |
C max (pg/mL) | 4,853,634 | 1,696,762 | 250,240 |
AUC(inf) (pg*hr/mL) | 37,378,687 | 28,185,225 | 426,747 |
Half life (hr) | 9.3 | 13.7 | 0.4 |
Claims (14)
- 2개 이상의 유비퀴틴이 공유결합되어 형성된 폴리유비퀴틴 스캐폴드, 및 서로 다른 결합 부위 (binding sites)에 대해 특이적인 결합 모이어티 (binding moieties)를 포함하는 2개 내지 10개의 생체분자를 포함하는, 다기능성 다중특이적 생체분자 중합체로서,상기 생체분자는 다른 생체분자, 저분자 화합물 (small molecule chemical compounds) 또는 나노입자와 특이적으로 결합하는 활성부위 (active sites)를 포함하고, 상기 유비퀴틴의 N-말단, C-말단, 또는 N-말단 및 C-말단 둘 모두에 직접 결합되거나 링커에 의해 결합되며,상기 생체분자의 생체 내 안정성 및 지속시간을 연장하는 캐리어 (carrier)가 상기 유비퀴틴의 N-말단, C-말단, 또는 N-말단 및 C-말단 둘 모두에 직접 결합되거나 링커에 의해 결합된 것인,다기능성 다중특이적 멀티머 생체분자 중합체 (multivalent multispecific multimeric biomolecule complex).
- 제1항에 있어서, 상기 링커는 GGGGS 또는 EAAAK가 1개 내지 30개 반복하여 조합된 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 유비퀴틴의 N-말단에 결합된 생체분자는 상기 멀티머 생체분자 중합체의 원위 말단 (distal end)인 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 유비퀴틴의 C-말단 또는 N-말단, 또는 둘 모두에 결합된 생체분자는 멀티머 생체분자 중합체의 근위 말단 (proximal end)인 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 캐리어는 알부민, 항체단편, Fc domain, transferrin, XTEN (genetic fusion of non-exact repeat peptide sequence), CTP (carboxy-terminal peptide), PAS (proline-alanine-serine polymer), ELK (elastin-like peptide), HAP (homo-amino acid polymer), GLK (gelatin-like protein), PEG (poly ethylene glycol), 및 지방산 (fatty acid)으로 구성된 군으로부터 선택된 하나 이상인 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 폴리유비퀴틴 스캐폴드는 유비퀴틴의 하나 이상의 라이신이 아르기닌 또는 알라닌을 포함한 다른 아미노산으로 치환된 것인 공여체 유비퀴틴과 N-말단으로부터 6번째, 11번째, 27번째, 29번째, 33번째, 48번째 또는 63번째 라이신이 아르기닌 또는 알라닌을 포함한 다른 아미노산으로 치환된 것인 수용체 유비퀴틴이 공유결합을 통해 연결되어 형성된 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 유비퀴틴의 N말단에서부터 73번째 류신이 프롤린을 포함한 다른 아미노산으로 치환된 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- 제1항 또는 제2항에 있어서, 상기 생체분자는 인슐린, 인슐린 유사체, 글루카곤, 글루카곤-유사 펩타이드류, GLP-1 및 글루카곤 이중 작용제, GLP-1 및 GIP 이중 작용제, GLP-1 및 글루카곤 및 GIP 삼중 작용제, 엑센딘-4 (exendin-4), 엑센딘-4 (exendin-4) 유사체, 인슐린 분비 펩타이드 및 그 유사체, 인간 성장 호르몬 (human growth hormone), 성장호르몬 방출 호르몬 (GHRH), 성장 호르몬 방출 펩타이드, 과립구집락자극인자 (G-CSF), 항비만 펩타이드, 지프로테인 관련 수용체 (G-protein-coulped receptor), 랩틴, GIP (Gastric inhibitory polypeptide), 인터루킨류, 인터루킨 수용체류, 인터루킨 결합 단백질류, 인터페론류, 인터페론 수용체류, 사이토카인 결합 단백질류, 마크로파지 활성인자, 마크로파지 펩타이드, B 세포인자, T 세포인자, 알러지 억제인자, 세포 괴사 당단백질, 면역독소, 림포독소, 종양 괴사인자 (TNF), 종양 억제인자, 전이 성장인자, 알파-1 안티트립신, 알부민, α-락트알부민, 아포리포단백질-E, 적혈구 생성인자 (EPO), 고당쇄화 적혈구생성인자, 안지오포이에틴류, 헤모글로빈, 크롬빈, 트롬빈 수용체 활성 펩타이드, 트롬보모듈린, 혈액인자 VII, VIIa, VIII, IX, 및 XIII, 플라즈미노젠 활성인자, 피브린-결합 펩타이드, 유로키나제, 스트렙토키나제, 히루딘, 단백질 C, C-반응성 단백질, 레닌 억제제, 콜라게나제 억제제, 수퍼옥사이드 디스뮤타제, 혈소판 유래 성장인자 상피세포 성장인자, 표피세포 성장인자, 안지오스타틴, 안지오텐신, 골 형성 성장인자, 골 형성 촉진 단백질, 칼시토닌, 아트리오펩틴, 연골 유도인자, 엘카토닌, 결합조직 활성인자, 조직인자 경로 억제제, 여포자극 호르몬 (FSH), 황체 형성 호르몬 (LH), 황체 형성 호르몬 방출 호르몬 (LHRH), 신경 성장인자류, 부갑상선 호르몬 (PTH), 릴랙신, 씨크레틴, 소마토메딘, 부신피질 호르몬, 콜레시스토키닌, 췌장 폴리펩타이드, 가스트린 방출 펩타이드, 코티코트로핀 방출인자, 갑상선 자극호르몬 (TSH), 오토탁신, 락토페린, 미오스타틴, 수용체, 수용체 길항물질, 섬유아세포 성장인자 (Fibroblast growth factor), 아디포넥틴 (Adiponectin), 인터루킨 수용체 길항제 (interleukin receptor antagonist), 세포표면항원, 바이러스 유래 백신 항원, 단일클론 항체, 다중클론 항체 및 항체 단편류로 이루어진 군으로부터 선택된 것인, 다기능성 다중특이적 멀티머 생체분자 중합체.
- (i) 유비퀴틴 C-말단 태그 (tag)가 융합 또는 링커에 의해 결합된 생체분자 (bio-molecules)를 원핵세포 또는 진핵세포를 포함하는 숙주세포로부터 재조합 발현시키고, 및(ii) 상기 숙주세포의 용해물 (cell lysates) 또는 정제산물에 유비퀴틴화를 위한 E1, E2 및 E3 효소, 또는 E1 및 E2 효소를 가하고 반응시키는 것을 포함하고,폴리유비퀴틴 스캐폴드, 서로 다른 결합 부위 (binding sites)에 대해 특이적인 결합 모이어티 (binding moieties)를 포함하는 2개 이상의 생체분자 및 생체내 지속시간을 연장하는 캐리어(carrier)가 유비퀴틴의 N-말단 또는 C-말단에 직접 또는 링커로 결합된, 다기능성 다중특이적 생체분자 중합체를 제조하는 방법으로서,상기 폴리유비퀴틴 스캐폴드는 2개 이상의 유비퀴틴이 공유결합을 통해 연결되어 형성되고,상기 생체분자는 2개 내지 10개의 생체분자로 구성되고, 다른 생체분자, 저분자 화합물 (small molecule chemical compounds) 또는 나노입자와 특이적으로 결합하는 활성부위 (active sites)를 가지며, 상기 유비퀴틴의 N-말단, C-말단, 또는 N-말단 및 C-말단 둘 모두에 링커로 결합된 것인,다기능성 다중특이적 멀티머 생체분자 중합체 (multivalent multispecific multimeric biomolecule complex)를 제조하는 방법.
- 제9항에 있어서, 상기 E2 효소는 유비퀴틴의 N-말단으로부터 6번째, 11번째, 27번째, 29번째, 33번째, 48번째 또는 63번째의 라이신과 결합하는 것인, 방법.
- 제9항 또는 제10항에 있어서, 상기 E2 효소는 E2-25K 유비퀴틴 컨주게이션 (ubiquitin conjugating) 효소인 것인, 방법.
- 제9항 또는 제10항에 있어서. 상기 E2 효소는 유비퀴틴 컨주게이션 효소 복합체인 Ucb13-MMS2인 것인, 방법.
- 제9항 또는 제10항에 있어서, 상기 유비퀴틴 C-말단 태그는 2개 이상의 유비퀴틴이 헤드-투-테일 (head-to-tail) 또는 분기 형태 (branched type or iso-peptide branch type) 형태로 반복 연결된 것인, 방법.
- 제13항에 있어서, 상기 헤드-투-테일 또는 분기 형태로 연결되는 유비퀴틴은, N 말단에서부터 75번째 및 76번째 글라이신이 발린을 포함한 다른 아미노산으로 치환된 것인, 방법.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2022006058A MX2022006058A (es) | 2019-11-27 | 2020-11-27 | Polimero de biomolecula multimerica multiespecifica multifuncional que tiene duracion prolongada in vivo. |
BR112022010445A BR112022010445A2 (pt) | 2019-11-27 | 2020-11-27 | Polímero biomolecular multifuncional, multiespecífico, multimérico , método para preparar um polímero biomolecular multifuncional, multiespecífico, multimérico |
CA3158903A CA3158903A1 (en) | 2019-11-27 | 2020-11-27 | Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration |
AU2020391285A AU2020391285B2 (en) | 2019-11-27 | 2020-11-27 | Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration |
IL293078A IL293078A (en) | 2019-11-27 | 2020-11-27 | A polymer of multi-functional, multi-specific biomolecules with prolonged in vivo duration |
JP2022530933A JP2023504790A (ja) | 2019-11-27 | 2020-11-27 | 生体内における持続時間が延長された多機能性多重特異性マルチマー生体分子重合体 |
CN202080082830.7A CN115244071A (zh) | 2019-11-27 | 2020-11-27 | 延长生物体内持续时间的多功能多特异性多聚体生物分子聚合物 |
EP20893956.1A EP4067373A4 (en) | 2019-11-27 | 2020-11-27 | MULTI-SPECIFIC MULTI-FUNCTIONAL MULTIMERIC BIOMOLECULE POLYMER WITH EXTENDED IN VIVO DURATION |
ZA2022/05789A ZA202205789B (en) | 2019-11-27 | 2022-05-25 | Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration |
CONC2022/0007332A CO2022007332A2 (es) | 2019-11-27 | 2022-05-27 | Polímero de biomolécula multimérico, multiespecífico y multifuncional que tiene una duración in vivo prolongada |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190154945 | 2019-11-27 | ||
KR10-2019-0154945 | 2019-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021107660A1 true WO2021107660A1 (ko) | 2021-06-03 |
Family
ID=75731250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/017029 WO2021107660A1 (ko) | 2019-11-27 | 2020-11-27 | 생체 내 지속시간이 연장된 다기능성 다중특이적 멀티머 생체분자 중합체 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4067373A4 (ko) |
JP (1) | JP2023504790A (ko) |
KR (1) | KR102243257B1 (ko) |
CN (1) | CN115244071A (ko) |
AU (1) | AU2020391285B2 (ko) |
BR (1) | BR112022010445A2 (ko) |
CA (1) | CA3158903A1 (ko) |
CO (1) | CO2022007332A2 (ko) |
IL (1) | IL293078A (ko) |
MX (1) | MX2022006058A (ko) |
WO (1) | WO2021107660A1 (ko) |
ZA (1) | ZA202205789B (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024019553A1 (ko) * | 2022-07-19 | 2024-01-25 | 주식회사 유비프로틴 | 보툴리눔 독소 a형 경쇄 단백질의 반감기를 증가시키는 방법 |
CN116199750A (zh) * | 2023-01-06 | 2023-06-02 | 吉林大学 | 一种核糖体蛋白s11及制备方法和在疫苗佐剂中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050050824A (ko) | 2003-11-26 | 2005-06-01 | 세메스 주식회사 | 베이크 장치에서의 웨이퍼 안착 상태를 감지하여 인터락을제어하기 위한 시스템 및 그의 제어 방법 |
KR20080080635A (ko) * | 2005-12-15 | 2008-09-04 | 제넨테크, 인크. | 폴리유비퀴틴 표적화를 위한 방법 및 조성물 |
WO2009009773A1 (en) * | 2007-07-11 | 2009-01-15 | The Johns Hopkins University | Use of otubain enzyme to cleave lysine-48-linked polyubiquitin |
US20130267680A1 (en) * | 2010-09-15 | 2013-10-10 | Stichting Het Nederlands Kankerinstituut | Total chemical synthesis of ubiquitin, ubiquitin mutants and derivatives thereof |
KR20140142293A (ko) * | 2012-03-16 | 2014-12-11 | 제넨테크, 인크. | 조작된 입체형태적으로-안정화된 단백질 |
KR20150120852A (ko) | 2014-04-18 | 2015-10-28 | 신-융 린 | 흡입형 통풍 치료용 약제 조성물 및 이의 제조 방법 |
WO2019007869A1 (en) * | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | TARGETED DEGRADATION OF PROTEINS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354722B1 (en) * | 1999-06-11 | 2008-04-08 | Signal Pharmaceuticals | Modulators of Smurf and BMP/TGFβ signaling pathways |
EP1284992A2 (en) * | 2000-05-30 | 2003-02-26 | Viridis Biotech Inc. | Polyubiquitin based hydrogel and uses thereof |
CN102753569A (zh) * | 2009-12-14 | 2012-10-24 | 塞尔蛋白质股份有限公司 | 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白 |
JP5543556B2 (ja) | 2012-09-05 | 2014-07-09 | 京セラ株式会社 | 携帯電子機器 |
KR101911438B1 (ko) * | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
KR20190135393A (ko) * | 2018-05-28 | 2019-12-06 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도 |
-
2020
- 2020-11-27 AU AU2020391285A patent/AU2020391285B2/en active Active
- 2020-11-27 BR BR112022010445A patent/BR112022010445A2/pt unknown
- 2020-11-27 KR KR1020200161909A patent/KR102243257B1/ko active IP Right Grant
- 2020-11-27 CN CN202080082830.7A patent/CN115244071A/zh active Pending
- 2020-11-27 EP EP20893956.1A patent/EP4067373A4/en active Pending
- 2020-11-27 IL IL293078A patent/IL293078A/en unknown
- 2020-11-27 MX MX2022006058A patent/MX2022006058A/es unknown
- 2020-11-27 WO PCT/KR2020/017029 patent/WO2021107660A1/ko active Application Filing
- 2020-11-27 JP JP2022530933A patent/JP2023504790A/ja active Pending
- 2020-11-27 CA CA3158903A patent/CA3158903A1/en active Pending
-
2022
- 2022-05-25 ZA ZA2022/05789A patent/ZA202205789B/en unknown
- 2022-05-27 CO CONC2022/0007332A patent/CO2022007332A2/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050050824A (ko) | 2003-11-26 | 2005-06-01 | 세메스 주식회사 | 베이크 장치에서의 웨이퍼 안착 상태를 감지하여 인터락을제어하기 위한 시스템 및 그의 제어 방법 |
KR20080080635A (ko) * | 2005-12-15 | 2008-09-04 | 제넨테크, 인크. | 폴리유비퀴틴 표적화를 위한 방법 및 조성물 |
WO2009009773A1 (en) * | 2007-07-11 | 2009-01-15 | The Johns Hopkins University | Use of otubain enzyme to cleave lysine-48-linked polyubiquitin |
US20130267680A1 (en) * | 2010-09-15 | 2013-10-10 | Stichting Het Nederlands Kankerinstituut | Total chemical synthesis of ubiquitin, ubiquitin mutants and derivatives thereof |
KR20140142293A (ko) * | 2012-03-16 | 2014-12-11 | 제넨테크, 인크. | 조작된 입체형태적으로-안정화된 단백질 |
KR20150120852A (ko) | 2014-04-18 | 2015-10-28 | 신-융 린 | 흡입형 통풍 치료용 약제 조성물 및 이의 제조 방법 |
WO2019007869A1 (en) * | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | TARGETED DEGRADATION OF PROTEINS |
Non-Patent Citations (2)
Title |
---|
CHRISTIAN RENZ, VERA TROSTER, THOMAS K. ALBERT , OLIVIER SANTT , SUSAN C. JACOBS , ANTON KHMELINSKII , HELLE D. ULRICH: "The ubiquitin-conjugating enzyme Ubc13-Mms2 cooperates with a family of FYVE-type-RING ubiquitin protein ligases in K63-polyubiquitylation at internal membranes", BIORXIV, 12 March 2019 (2019-03-12), pages 1 - 43, XP055817221, DOI: 10.1101/575241 * |
See also references of EP4067373A4 |
Also Published As
Publication number | Publication date |
---|---|
AU2020391285B2 (en) | 2024-05-23 |
ZA202205789B (en) | 2024-01-31 |
EP4067373A1 (en) | 2022-10-05 |
CA3158903A1 (en) | 2021-06-03 |
IL293078A (en) | 2022-07-01 |
CN115244071A (zh) | 2022-10-25 |
BR112022010445A2 (pt) | 2022-09-06 |
JP2023504790A (ja) | 2023-02-07 |
EP4067373A4 (en) | 2023-12-06 |
CO2022007332A2 (es) | 2022-08-30 |
AU2020391285A1 (en) | 2022-06-09 |
MX2022006058A (es) | 2022-07-27 |
KR102243257B1 (ko) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021107660A1 (ko) | 생체 내 지속시간이 연장된 다기능성 다중특이적 멀티머 생체분자 중합체 | |
WO2013100702A1 (en) | Immunoglobulin fc variants | |
WO2014133324A1 (ko) | 신규한 인슐린 아날로그 및 이의 용도 | |
WO2014193173A1 (ko) | 변이된 힌지 영역을 포함하는 igg4 fc 단편 | |
WO2015108398A1 (ko) | 지속형 인슐린 및 그 용도 | |
WO2013051900A2 (en) | Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2019066586A1 (ko) | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 | |
WO2017222337A1 (ko) | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 | |
WO2011053065A9 (ko) | 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법 | |
AU2014312456A8 (en) | An anti serum albumin Fab-effector moiety fusion construct, and the preparing method thereof | |
WO2019066570A1 (ko) | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 | |
WO2018174668A2 (ko) | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 | |
WO2019231208A1 (ko) | 폴리유비퀴틴 링커에 결합된 선형 다기능성 멀티머 생체분자 및 이의 용도 | |
WO2015199441A1 (ko) | 피키아 파스토리스 균주 유래의 목적단백질 분비생산용 단백질융합인자 및 이의 용도 | |
WO2018004294A2 (ko) | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 | |
WO2022131764A1 (ko) | 세포막 투과성을 갖는 신규 펩타이드 | |
WO2021107519A1 (en) | Biotin moiety-conjugated polypeptide and pharmaceutical composition for oral administration comprising the same | |
WO2011049350A2 (ko) | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 | |
WO2017052324A1 (en) | Method of producing immunoglobulin fc region including initial methionine residue | |
Hui et al. | Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase | |
WO2024090815A1 (ko) | 식물로부터 인유두종 바이러스 유사 입자의 생산 | |
WO2021010531A1 (ko) | 단백질 결합체의 신규 제조 방법 | |
WO2020032423A1 (ko) | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 | |
WO2019103512A9 (ko) | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20893956 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3158903 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 788436 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2022530933 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022010445 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020391285 Country of ref document: AU Date of ref document: 20201127 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020893956 Country of ref document: EP Effective date: 20220627 |
|
ENP | Entry into the national phase |
Ref document number: 112022010445 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220527 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522432739 Country of ref document: SA |